Publication:
Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.

Simple item page
dc.contributor.authorPalomar Muñoz, Azahara
dc.contributor.authorCordero García, José Manuel
dc.contributor.authorTalavera Rubio, Mª Del Prado
dc.contributor.authorGarcía Vicente, Ana Mª
dc.contributor.authorPena Pardo, Francisco José
dc.contributor.authorJiménez Londoño, Germán Andrés
dc.contributor.authorSoriano Castrejón, Ángel
dc.contributor.authorAranda Aguilar, Enrique
dc.date.accessioned2023-01-25T10:07:39Z
dc.date.available2023-01-25T10:07:39Z
dc.date.issued2018
dc.description.abstractTo assess the diagnostic accuracy of CA125, its kinetic values and positron emission tomography/computed tomography with 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG-PET/CT), in relation with tumor characteristics for suspected recurrence of ovarian cancer. To evaluate the performance of CA125-related parameters as a selection criteria to perform a [F]FDG-PET/CT.A retrospective analysis of 69 [F]FDG-PET/CT for suspected recurrence of ovarian cancer was performed. All patients had 2 measurements of CA125, before PET/CT, to calculate kinetic values, as CA125vel (CA125vel = [CA125a - CA125b]/time) and CA125dt (CA125dt = [log2 × time]/[logCA125a - CA125b]). Maximum standard uptake value (SUVmax) was calculated. The diagnostic accuracy was calculated for all the variables and the optimal cut-off value of each of them by the receiver-operating characteristics (ROC) analysis. All the tests were compared with tumor characteristics and clinical-radiological evolution during follow-up of at least 6 months.Fifty-five cases were diagnosed of recurrence (11 with CA125 
dc.identifier.doi10.1097/MD.0000000000010098
dc.identifier.essn1536-5964
dc.identifier.pmcPMC5944512
dc.identifier.pmid29702969
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944512/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1097/md.0000000000010098
dc.identifier.urihttp://hdl.handle.net/10668/12405
dc.issue.number17
dc.journal.titleMedicine
dc.journal.titleabbreviationMedicine (Baltimore)
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.page.numbere0098
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAged
dc.subject.meshBiomarkers, Tumor
dc.subject.meshCA-125 Antigen
dc.subject.meshEarly Detection of Cancer
dc.subject.meshFemale
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshOvarian Neoplasms
dc.subject.meshPositron Emission Tomography Computed Tomography
dc.subject.meshROC Curve
dc.subject.meshRetrospective Studies
dc.titleValue of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number97
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía